RedHill Biopharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 20, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	5	8	29	13	135	302
Market Cap Growth	-32.08%	-72.32%	124.48%	-90.53%	-55.27%	41.19%
Enterprise Value	2	1	24	118	188	353
Last Close Price	0.98	6.21	36.50	140.30	2580.00	8080.00
PE Ratio	-	-	1.20	-	-	-
PS Ratio	0.53	0.99	4.40	0.21	1.58	4.70
PB Ratio	-	-1.70	13.88	-0.26	15.23	21.80
EV/Sales Ratio	0.25	0.15	3.68	1.92	2.19	5.49
Debt / Equity Ratio	-0.05	-0.08	0.57	-2.53	9.89	6.27
Net Debt / Equity Ratio	0.60	0.91	-2.12	-2.12	5.61	4.12
Net Debt / EBITDA Ratio	0.32	0.35	0.20	-2.96	-0.79	-1.04
Net Debt / FCF Ratio	0.32	0.45	0.12	-3.49	-0.76	-1.17
Asset Turnover	0.47	0.39	0.07	0.36	0.48	0.51
Inventory Turnover	0.97	0.79	0.45	2.58	4.63	8.78
Quick Ratio	0.37	0.34	0.44	0.28	0.87	0.81
Current Ratio	0.56	0.54	0.81	0.44	1.09	0.96
Return on Equity (ROE)	-	-	-	-	-859.70%	-206.25%
Return on Assets (ROA)	-25.32%	-37.28%	-15.71%	-15.75%	-28.06%	-31.30%
Return on Capital Employed (ROCE)	209.20%	293.20%	-746.30%	111.00%	-81.40%	-59.50%
Earnings Yield	-185.30%	-103.97%	83.26%	-560.09%	-72.30%	-25.20%
FCF Yield	-163.37%	-117.93%	-124.74%	-229.63%	-48.20%	-16.21%
Buyback Yield / Dilution	-97.35%	-375.56%	-320.45%	-32.46%	-27.72%	-22.69%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q